NRx Pharmaceuticals, Inc. (NRXP)
$1.23
-0.02 (-1.60%)
Rating:
Recommendation:
-
| Symbol | NRXP |
|---|---|
| Price | $1.23 |
| Beta | 0.989 |
| Volume Avg. | 0.38M |
| Market Cap | 83.260M |
| Shares () | - |
| 52 Week Range | 0.49-3.54 |
| 1y Target Est | - |
| DCF Unlevered | NRXP DCF -> | |
|---|---|---|
| DCF Levered | NRXP LDCF -> | |
| ROE | 86276.76% | Strong Buy |
| ROA | 82221.68% | Strong Buy |
| Operating Margin | - | |
| Debt / Equity | 47.92% | Neutral |
| P/E | - | |
| P/B | 4.87 | Strong Buy |
Latest NRXP news
About
Download (Excel)Mr. Richard S. Ackerman J.D.
Healthcare
Biotechnology
NASDAQ Global Market
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.